MX2022010280A - Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias. - Google Patents

Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.

Info

Publication number
MX2022010280A
MX2022010280A MX2022010280A MX2022010280A MX2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A MX 2022010280 A MX2022010280 A MX 2022010280A
Authority
MX
Mexico
Prior art keywords
arginine
methods
cells
car
compositions
Prior art date
Application number
MX2022010280A
Other languages
English (en)
Spanish (es)
Inventor
Kwok Ming Cheung
Original Assignee
Sky Perfect International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky Perfect International Ltd filed Critical Sky Perfect International Ltd
Publication of MX2022010280A publication Critical patent/MX2022010280A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MX2022010280A 2020-02-21 2021-02-20 Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias. MX2022010280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979805P 2020-02-21 2020-02-21
PCT/CN2021/077002 WO2021164753A1 (en) 2020-02-21 2021-02-20 Methods and compositions for modulating arginine levels in immune cells

Publications (1)

Publication Number Publication Date
MX2022010280A true MX2022010280A (es) 2022-11-16

Family

ID=77390457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010280A MX2022010280A (es) 2020-02-21 2021-02-20 Metodos y composiciones para modular las concentraciones de arginina en celulas inmunitarias.

Country Status (13)

Country Link
US (1) US20230265386A1 (cg-RX-API-DMAC7.html)
EP (1) EP4107254A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023515806A (cg-RX-API-DMAC7.html)
KR (1) KR20220157396A (cg-RX-API-DMAC7.html)
CN (1) CN115427553A (cg-RX-API-DMAC7.html)
AR (1) AR121392A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021223138A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016571A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171901A1 (cg-RX-API-DMAC7.html)
IL (1) IL295606A (cg-RX-API-DMAC7.html)
MX (1) MX2022010280A (cg-RX-API-DMAC7.html)
TW (1) TW202144569A (cg-RX-API-DMAC7.html)
WO (1) WO2021164753A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
CN114788870B (zh) * 2022-04-29 2023-06-06 浙江大学 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用
WO2026063691A1 (ko) * 2024-09-20 2026-03-26 삼성바이오에피스 주식회사 아르기니노숙시네이트 합성효소를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
EP3525803B1 (en) * 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins

Also Published As

Publication number Publication date
IL295606A (en) 2022-10-01
TW202144569A (zh) 2021-12-01
AU2021223138A1 (en) 2022-09-29
AR121392A1 (es) 2022-06-01
US20230265386A1 (en) 2023-08-24
JP2026063215A (ja) 2026-04-10
CA3171901A1 (en) 2021-08-26
EP4107254A1 (en) 2022-12-28
CN115427553A (zh) 2022-12-02
KR20220157396A (ko) 2022-11-29
WO2021164753A1 (en) 2021-08-26
BR112022016571A2 (pt) 2022-11-16
JP2023515806A (ja) 2023-04-14
EP4107254A4 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
AR121392A1 (es) Métodos y composiciones para modular los niveles de arginina en células inmunitarias
Wang et al. Role of mitochondrial alterations in human cancer progression and cancer immunity
Li et al. Uptake and protective effects of ergothioneine in human endothelial cells
Wang et al. Inverse relationship between elemental selenium nanoparticle size and inhibition of cancer cell growth in vitro and in vivo
Queiroga et al. Carbon monoxide targeting mitochondria
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
Trefny et al. Metabolites as agents and targets for cancer immunotherapy
MX2013010793A (es) Metodo y composiciones para inmunoterapia celular.
US20220105186A1 (en) Compositions Containing Nucleosides and Manganese and Their Uses
ECSP22056585A (es) Variantes de alfa-glucosidasa ácida diseñadas por ingeniería
Almeida et al. Carbon monoxide improves neuronal differentiation and yield by increasing the functioning and number of mitochondria
MX2024002436A (es) Celulas que expresan il-10 para inmunoterapias mejoradas contra el cancer.
Farahzadi et al. Investigation of L-carnitine effects on CD44+ cancer stem cells from MDA-MB-231 breast cancer cell line as anti-cancer therapy
CL2022002150A1 (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
MX2021006504A (es) Terapia combinada de moleculas de reclutamiento de anticuerpos (arms) y celulas asesinas naturales.
Feng et al. Biogenic polyphosphate nanoparticles from Synechococcus sp. PCC 7002 exhibit intestinal protective potential in human intestinal epithelial cells in vitro and murine small intestine ex vivo
ES2690545T3 (es) Combinación de EPA, DPA y/o DHA con un agente quimioterapéutico
Kim et al. Radioprotective effects of delphinidin on normal human lung cells against proton beam exposure
CN102946888B (zh) 含有嘌呤和嘧啶核苷、肽和锰的组合物及其用途
Tuji et al. Ultrastructural assessment of the radioprotective effects of sodium selenite on parotid glands in rats
MX2021010998A (es) Metodos para mejorar la eficacia en el agotamiento de celulas tcr a?+.
Wong et al. Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.
WO2024059757A3 (en) Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer
CL2023002602A1 (es) Uso de células madre mesenquimales sobreexpresoras de pacer para el tratamiento de enfermedades con origen y/o componente inflamatorio
MX2024011575A (es) Terapia celular